Baxter (BAX) is a publicly traded Healthcare sector company. As of May 21, 2026, BAX trades at $18.76 with a market cap of $9.19B and a P/E ratio of -9.93. BAX moved +2.56% today. Year to date, BAX is -5.63%; over the trailing twelve months it is -40.34%. Its 52-week range spans $15.73 to $39.57. Analyst consensus is neutral with an average price target of $20.38. Rallies surfaces BAX's financials, insider trades, hedge fund holdings, congressional trades, analyst ratings, and AI-generated research below.
Baxter drops as Q1 2026 earnings release hits tape on May 13: Baxter reported first-quarter 2026 results dated May 13, 2026, including a GAAP EPS loss of ($0.03) and adjusted EPS of $0.36. The same-day earnings release is a concrete catalyst that can plausibly explain the stock’s move.
| Metric | Value |
|---|---|
| Price | $18.76 |
| Market Cap | $9.19B |
| P/E Ratio | -9.93 |
| EPS | $-1.87 |
| Dividend Yield | 0.01% |
| 52-Week High | $39.57 |
| 52-Week Low | $15.73 |
| Volume | 5.39M |
| Avg Volume | 0 |
| Revenue (TTM) | $11.24B |
| Net Income | $-957.00M |
| Gross Margin | 30.05% |
9 analysts cover BAX: 0 strong buy, 2 buy, 6 hold, 1 sell, 0 strong sell. Consensus rating is neutral. Average price target: $20.38.